$RGDXQ Asset Value: $0.361 per share. Response develops, manufactures and markets rapid onsite diagnostic tests for use with its RAMP platform for clinical, biodefense and environmental applications.
RAMP represents a unique paradigm in diagnostics that provides reliable, quality results in minutes.
The RAMP platform consists of a reader and single use disposable test cartridges and has the potential to be adapted to any other medical and nonmedical immunoassay based test currently performed in laboratories.
Response clinical tests are commercially available for the aid in early detection of heart attack, congestive heart failure, thromboembolism and infectious diseases.
In the nonclinical market, RAMP tests are currently available for the environmental detection of West Nile Virus antigen and for Biodefense applications including the rapid onsite detection of anthrax, smallpox, ricin and botulinum toxin.
Latest News JUN 1, 2020 Cancer Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Strategic Business Updates https://www.cancergenetics.com/
Business Description;
We are a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer (theranosis).
Our proprietary tests target cancers where prognosis information is critical and where predicting treatment outcomes using currently available techniques is limited.
These cancers include ematological, urogenital and HPV-associated cancers.
We have commercially launched MatBA -CLL and -SLL, our first proprietary microarray diagnostic tests, and seek to provide our tests and services to oncologists and pathologists at hospitals, cancer centers and physician offices, as well as to biopharmaceutical companies and clinical research organizations for their clinical trials.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.